Is MIS-C (Multisystem Inflammatory Syndrome in Children) a Vaccine-Preventable Disease?

Mangat, Chetna; Milosavljevic, Natasa

doi:10.1177/00099228221083894

Cited by 2 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On October, 2021 the Pfizer-BioNTech vaccine was approved by the FDA for children aged 5–11 years [ 2 , 3 ]. Therefore, the preventive effect seen in adolescents has not yet been evaluated in these younger children [ 38 ]. In 2021, the CDC mentioned that MIS-C was most frequent among children 5–11 years, with 2,316 cases of MIS-C reported in the United States at that time [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…The epidemiology of the COVID-19 virus is changing constantly, and the Omicron variant may lead to a milder disease course but might be also more contagious [ 38 ]. It is not known yet if the Omicron variant is more or less associated with MIS-C compared to other variants [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

“…The studies included in this systematic review were conducted during a period when the Delta variant was dominant and Omicron was looming [ 38 ]. The question arises, whether the conclusions that were made about the Delta era can be translated to the Omicron era.…”

Section: Discussionmentioning

confidence: 99%

“…The question arises, whether the conclusions that were made about the Delta era can be translated to the Omicron era. The CDC reported that Omicron has a higher transmission rate [ 38 ]. Since Omicron has become dominant, researchers have focused on comparing COVID-19 and MIS-C cases between the Delta and Omicron era.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis

Hamad Saied,

van der Griend,

van Straalen

et al. 2023

Pediatr Rheumatol

View full text Add to dashboard Cite

Objective To review whether the current COVID-19 vaccines can prevent the occurrence of multisystem inflammatory syndrome in children (MIS-C) and adolescents. Methods A systematic literature review and meta-analysis were performed. The data were abstracted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Primary outcome was the efficacy of COVID-19 vaccination in preventing MIS-C development. The search was performed in PubMed and Embase. Results The review yielded 13 studies, which were included for critical appraisal and data extraction. The available studies showed a reduced incidence of MIS-C after mRNA COVID-19 vaccination in children aged 12–18 years. Four studies were eligible for meta-analysis and the pooled odds ratio for MIS-C in vaccinated children compared to unvaccinated children was 0.04 (95% confidence interval: 0.03–0.06). Additionally, the risk of MIS-C as an adverse effect of vaccination was much lower compared to the risk of MIS-C post-infection. Conclusions Our systematic review highlights the current available evidence on the efficacy of COVID-19 vaccination in preventing MIS-C. The published studies so far – mainly conducted during the Delta wave – indicate that (original strain) COVID-19 mRNA vaccines in children are safe and associated with significantly less development of MIS-C. These findings further reinforce the recommendation for COVID-19 vaccination in children, which should be promoted and largely supported.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis

Hamad Saied,

van der Griend,

van Straalen

et al. 2023

Pediatr Rheumatol

View full text Add to dashboard Cite

show abstract

“…American Academy of Pediatrics (AAP) and CDC guidelines recommend routine COVID-19 vaccination for children older than 6 months of age [107]. As there is a growing body of evidence in favor of vaccines being highly effective against MISC, to keep on vaccinating children is encouraged [108].…”

Section: Preventionmentioning

confidence: 99%

A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children

Haşlak

Günalp

Kasapçopur

2022

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of reviewWe aimed to summarize a novel disease called multisystem inflammatory syndrome in children (MIS-C), which develops several weeks after a severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) illness. Recent findingsGiven the rarity of the disease, the question of why a minority of children develop MIS-C is not known. Certain intrinsic susceptibility factors in the host have been described. In addition to hyperinflammation induced by the innate and acquired immune cells, evidence of molecular mimicry was presented for the disease pathogenesis. As there is an increasing number of infected individuals and mass vaccination schedules, concerns regarding the usefulness of the existing diagnostic criteria sets raised.

show abstract

Is MIS-C (Multisystem Inflammatory Syndrome in Children) a Vaccine-Preventable Disease?

Cited by 2 publications

References 14 publications

The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis

The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis

A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children

Contact Info

Product

Resources

About